174 related articles for article (PubMed ID: 36736729)
1. Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin.
García-Arnés JA; García-Casares N
Rev Clin Esp (Barc); 2023 Mar; 223(3):181-187. PubMed ID: 36736729
[TBL] [Abstract][Full Text] [Related]
2. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Tentori L; Graziani G
Pharmacol Res; 2007 May; 55(5):359-69. PubMed ID: 17349798
[TBL] [Abstract][Full Text] [Related]
3. Hormone abuse in sports: the antidoping perspective.
Barroso O; Mazzoni I; Rabin O
Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
[TBL] [Abstract][Full Text] [Related]
4. [Recent advances in the detection of human erythropoietin and human growth hormone doping].
Guo L; Zhang Z; Tang J; Xie J
Se Pu; 2008 Jul; 26(4):437-43. PubMed ID: 18959238
[TBL] [Abstract][Full Text] [Related]
5. IGF-I abuse in sport.
Guha N; Dashwood A; Thomas NJ; Skingle AJ; Sönksen PH; Holt RI
Curr Drug Abuse Rev; 2009 Sep; 2(3):263-72. PubMed ID: 20443773
[TBL] [Abstract][Full Text] [Related]
6. [Growth hormone and IGF-1 as doping agents in competitive sport].
Jóźków P; Medraś M
Endokrynol Pol; 2009; 60(5):389-94. PubMed ID: 19885810
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone, IGF-I and insulin and their abuse in sport.
Holt RI; Sönksen PH
Br J Pharmacol; 2008 Jun; 154(3):542-56. PubMed ID: 18376417
[TBL] [Abstract][Full Text] [Related]
8. Use of hormones in doping and cancer risk.
De Santi M; Baldelli G; Brandi G; ;
Ann Ig; 2019; 31(6):590-594. PubMed ID: 31616903
[TBL] [Abstract][Full Text] [Related]
9. Report on an anti-doping operation in Guadeloupe: High number of positive cases and inferences about doping habits.
Marchand A; Buisson C; Martin L; Martin JA; Molina A; Ressiot D
Drug Test Anal; 2017 Nov; 9(11-12):1753-1761. PubMed ID: 28296276
[TBL] [Abstract][Full Text] [Related]
10. Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.
Gild ML; Stuart M; Clifton-Bligh RJ; Kinahan A; Handelsman DJ
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3562-e3573. PubMed ID: 35438767
[TBL] [Abstract][Full Text] [Related]
11. Overview of the legal framework applicable to the marker method for the detection of human growth hormone.
Young RR; Bielak JS; Horvitz SL
Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446
[TBL] [Abstract][Full Text] [Related]
12. [Doping and urologic tumors].
Pinto F; Sacco E; Volpe A; Gardi M; Totaro A; Calarco A; Racioppi M; Gulino G; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):92-9. PubMed ID: 20890867
[TBL] [Abstract][Full Text] [Related]
13. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
Yu NH; Ho EN; Wan TS; Wong AS
Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
[TBL] [Abstract][Full Text] [Related]
14. Doping and sports endocrinology: anabolic-androgenic steroids.
García-Arnés JA; García-Casares N
Rev Clin Esp (Barc); 2022 Dec; 222(10):612-620. PubMed ID: 36400345
[TBL] [Abstract][Full Text] [Related]
15. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
[TBL] [Abstract][Full Text] [Related]
16. Analytical challenges in the detection of peptide hormones for anti-doping purposes.
Barroso O; Handelsman DJ; Strasburger C; Thevis M
Bioanalysis; 2012 Jul; 4(13):1577-90. PubMed ID: 22831474
[TBL] [Abstract][Full Text] [Related]
17. Doping in the recombinant era: strategies and counterstrategies.
Azzazy HM; Mansour MM; Christenson RH
Clin Biochem; 2005 Nov; 38(11):959-65. PubMed ID: 16286094
[TBL] [Abstract][Full Text] [Related]
18. Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol.
Reichel C; Erceg D; Lorenc B; Scheiblhofer V; Farmer L; Zanitzer K; Geisendorfer T; Gmeiner G; Thevis M
Drug Test Anal; 2023 Feb; 15(2):163-172. PubMed ID: 33450134
[TBL] [Abstract][Full Text] [Related]
19. The future of doping control in athletes. Issues related to blood sampling.
Birkeland KI; Hemmersbach P
Sports Med; 1999 Jul; 28(1):25-33. PubMed ID: 10461710
[TBL] [Abstract][Full Text] [Related]
20. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Thomas A; Walpurgis K; Thevis M
J Mass Spectrom; 2024 Jan; 59(1):e4996. PubMed ID: 38197510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
